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S u m m a r y
Introduction. Transforming Growth Factor β (TGFβ) activates signaling cascades 
which regulate cell proliferation, differentiation, apoptosis, inflammatory response and 
angiogenesis. In the early stages of malignant transformation this cytokine acts as an 
inhibitor of tumour growth. In the advanced stages of malignant transformation TGFβ acts 
as a promoter of metastasis. Changes in the expression of genes associated with TGFβ 
activity could provide a new strategy of molecularly targeted therapy.
Aim. The aim of this study was to compare the mRNA profile of genes associated with 
TGFβ signaling pathways in non-melanoma skin pathologies biopsy specimens of bas-
al cell carcinoma (BCC), squamous cell carcinoma (SCC) and keratoacanthoma (KA) in 
comparison to normal skin.
Material and methods. Tissue samples of KA, SCC and BCC were obtained from the 
central part of tumours. Healthy skin margins comprised the control group. mRNA profile 
of genes coding TGFβ and proteins involved in TGFβ-induced signaling pathways was 
determined using oligonucleotide microarrays (Affymetrix).
Results. Microarray analysis showed changes in profile of genes coding proteins in-
volved in TGFβ-induced signaling pathways. In SCC TGFβ-1 (TGFB1) was upregulated, 
comparing to controls. Both in KA and SCC, the most statistically significant change re-
ferred to TGFBR3 (Transforming Growth Factor beta Receptor III) mRNA.
Conclusions. mRNA profile of genes coding proteins involved in TGFβ-induced signal-
ization reveals strong molecular similarity of SCC and KA.
S t r e s z c z e n i e
Wstęp. Transformujący czynnik wzrostu β (TGFβ) aktywuje kaskady sygnałowe re-
gulujące proliferację komórek, ich różnicowanie, apoptozę, odpowiedź immunologiczną 
i angiogenezę. W początkowych stadiach transformacji nowotworowej cytokina ta pełni 
funkcję inhibitora wzrostu guza. W zaawansowanych stadiach TGFβ działa jako promotor 
przerzutowania. Zmiany ekspresji genów powiązanych z aktywnością biologiczną TGFβ 
mogą przyczynić się do opracowania nowej strategii molekularnie ukierunkowanej terapii.
Cel pracy. Celem pracy było porównanie profilu ekspresji genów powiązanych z sy-
gnalizacją indukowaną przez TGFβ w niemelanotycznych patologiach skóry: raku pod-
stawnokomórkowym (BCC), raku kolczystokomórkowym (SCC) oraz rogowiaku kolczy-
stokomórkowym (KA), w porównaniu do kontroli.
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INTRODUCTION
Molecular studies carried out at different levels of 
the flow of genetic information, allow precise charac-
terization of what is really happening in normal cells 
or pathologically changed. Knowledge and under-
standing of the mechanisms responsible for the in-
duction and progression of malignant transformation 
becomes more and more likely, what in the future may 
result in a modification of diagnostic algorithms and 
personalization of molecularly targeted therapy. Inte-
grated analysis is made possible by the large-scale 
research platforms adapted to evaluate the integrity 
of the genome (whole-genome microarrays), analysis 
of transcriptome changes (expression microarrays), 
the analysis of the mechanisms responsible for tran-
scription regulation (epigenetic control), metabolomics 
(phenotypic microarrays), the analysis of proteome 
(protein microarray) or kinomics (the state of proteins’ 
phosphorylation).
The TGFβ superfamily includes a large group 
of structurally related regulatory proteins with over 
60 members, including at least 29-42 representatives 
encoded by the human genome (1). Until recently, 
the family TGFβ was divided into two basic subfami-
lies: TGF /Activins and BMP/GDF (bone morphogenetic 
protein/growth and differentiation factor) (2). Currently 
it is divided into 4 main groups: 1) TGFβ, 2) activins 
and inhibins, 3) bone morphogenetic proteins (BMPs) 
including at least 11 growth and differentiation fac-
tors – GDFs, and 4) MIF (also known as anti-Müllerian 
hormone – AMH) or MIS (Müllerian inhibitory sub-
stance) (3). TGFβ group comprise of five molecular iso-
forms not related to TGFα and each of them is encoded 
by separate gene. Three isoforms have been identified 
in mammals: TGFβ1, TGFβ2, TGFβ3. They are pleiotro-
pic cytokines involved in cell cycle regulation (4), differ-
entiation (5), apoptosis (6), cel migration (7) and in the 
formation and degradation of extracellular matrix com-
ponents (8) including type I collagen (9). These factors 
are suppressors of proliferation of vascular endothelial 
cells and hematopoietic cells (10), significantly affect-
ing the regulation of the immune response (4). In ad-
vanced stages of cancer of TGFβ acts as a promoter of 
metastasis by: modulating the microenvironment of the 
tumor cells and extracellular matrix synthesis, induc-
tion of chemokines secretion, silencing immunological 
response and participation in epithelial-mesenchymal 
transition (EMT) (11). Signaling pathways in tumors 
induced by TGFβ ligands may lead to inhibition of car-
cinogenesis or progression of cancer, depending on 
cancer staging (12). In the early stages of malignant 
transformation TGFβ activates signaling cascades 
which stimulate the expression of genes involved in in-
hibition of proliferation, cell differentiation stimulation, 
apoptosis or autophagy activation, suppression of an-
giogenesis and inflammatory response (13). In the ad-
vanced stages of the disease TGFβ acts as a promoter 
of metastasis through participation in epithelial-mes-
enchymal transition, remodeling of extracellular matrix 
and the microenvironment of tumor cells, inducing the 
synthesis of chemokines and immune response silenc-
ing (14).
TGFβ acts through two types of transmembrane 
serine-threonine kinase receptors: TβRI (TGFβR1) and 
TβRII (TGFβR2). In mammalian cells are present five 
kinds of receptor type II, seven kinds of type I and three 
kinds of type III receptor, which are involved in signal 
transduction activated by transforming growth factor 
as accessory/auxiliary receptors. These proteins have 
no functional intracellular domain, and therefore are 
not direct signal transmitters. Their involvement in the 
regulation of signaling pathways activity triggered by 
TGFβ involves presenting of cytokines to TGFβR1 and 
TGFβR2 receptors or limiting of their interaction with re-
ceptors. This type of receptors is specific only for TGFβ 
receptors group and is particularly important for TGFβ2 
isoform, which has very low affinity for TGFβR2 and re-
quires the presence of an auxiliary receptor TGFβR3 
to facilitate formation of complexes with TGFβR2 (15). 
TGFβ type I receptors, known as ALK (Activin-like ki-
nase) consist of the extracellular binding domain, 
transmembrane domain and a 30 amino acid regu-
latory region, rich in repeating glycine and serine 
residues (GS region) located above the catalytic do-
main of serine-threonine kinase (16). Type II recep-
tors (TGFβR2), like TGFβR1, consist of the N-terminal 
extracellular ligand binding domain with characteristic 
cysteine CXCX4C pattern, transmembrane region and 
a C-terminal domain with serine-threonine kinase activ-
ity (3). Five receptors of TGFβ type II have been de-
scribed: BMP receptor (BMP RII), activin type II recep-
tor (Act RII), activin receptor β – Act RIIβ and Müllerian 
inhibitory substance type II receptor (MIS RII) (17). After 
binding with a ligand type II receptors  phosphorylate 
Materiał i metody. Wycinki pobrano z centrum guza (BCC, SCC i KA) oraz margi-
nesów tkanki histopatologicznie prawidłowej (kontrole). Profil mRNA genów kodujących 
TGFβ oraz białka zaangażowane w sygnalizację indukowaną przez TGFβ wyznaczono 
techniką mikromacierzy oligonukleotydowych (Affymetrix).
Wyniki. Analiza techniką mikromacierzy wykazała zmiany w profilu genów kodujących 
białka zaangażowanego w sygnalizację indukowaną przez TGFβ. W porównaniu do kon-
troli, w SCC stwierdzono nadekspresję TGFβ-1 (TGFB1). Zarówno w SCC, jak i w KA naj-
większą zmianę wykazał gen kodujący receptor III dla TGFβ (TGFBR3).
Wnioski. Profil ekspresji genów kodujących TGFβ oraz białka zaangażowane w sy-
gnalizację indukowaną przez TGFβ wykazuje silne molekularne podobieństwo pomiędzy 
SCC i KA.
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type I receptors, resulting in activation of SMAD family 
transcription factors – involved in the canonical TGFβ 
signaling pathway (16).
TGFβ and its antagonists have enormous potential 
in the treatment of diseases that are now resistant to 
conventional therapy. Analysis of gene expression as-
sociated with TGFβ activity and the design of additional 
analogs and antagonists of TGFβ is an object of many 
studies aimed at developing new molecularly targeted 
treatment strategies (18).
AIM
The aim of this study is to compare the concentra-
tion profile of 1050 mRNA associated with Transforming 
Growth Factor beta (TGFβ) signaling pathways in cancer 
biopsy specimens of basal cell carcinoma (BCC), squa-
mous cell carcinoma (SCC) and keratoacanthoma (KA) 
in comparison to normal skin and selecting mRNA signifi-
cantly differentiating analyzed transcriptomes.
MATERIAL AND METHODS
Material
The study included a group of 39 patients diag-
nosed and treated in the Dermatology Clinics and 
Department of Medical University of Silesia in Kato-
wice. The tumours located on the skin of the face 
and head were pathomorphologically and clinically 
examined. Based on these results 19 samples were 
enrolled to transcriptome analysis: 6 cases of kera-
thoacanthoma (KA), 3 cases of squamous cell car-
cinoma (SCC), 7 of basal cell carcinoma (BCC) and 
4 margins of healthy tissues. After surgical excision, 
tissue samples were immediately preserved in the 
RNA stabilisation reagent RNAlater (Qiagen GmbH, 
Hilden, Germany). All of the patients were informed 
about the research and signed an informed consent 
form. The study was approved by the Bioethical 
Commission of the Medical University of Silesia.
Extraction of total RNA
Total cellular RNA was isolated from tissue sam-
ples with the use of TRIZOL® reagent (Invitrogen 
Life Technologies, Kalifornia, USA), according to 
the manufacturer’s protocol. Extracts of total RNA 
were purified with the use of RNeasy Mini Kit (Qia-
gen Gmbh, Hilden, Germany) and treated with 
DNAase I (Fermentas International Inc., Ontario, 
Kanada) according to the manufacturer’s proto-
col. The RNA concentration was determined with 
the use of Gene Quant II spectrophotometer (Phar-
macia LKB Biochrom Ltd., Cambridge, UK). The 
quality of RNA was estimated electrophoretical-
ly (1% agarose gel stained with ethidium bromide).
Oligonucleotide microarray
10 µg of purified RNA was reverse transcribed 
with the use of SuperScript Choice System (Invit-
rogen Life Technologies, California, USA). dsDNA 
was purified using Phase Lock Gel Light (Eppen-
dorf, Germany). Synthesis of biotynylated cRNA 
was performed with the use of BioArray HighYield 
RNA Transcript Labeling Kit (Enzo Life Science, 
New York, USA). Biotynylated cRNA was purified 
using RNeasy Mini Kit (Qiagen Gmbh, Hilden, 
Germany). Fragmentation of 16 µg cRNA was 
performed with the use of Sample Cleanup Mod-
ule (Qiagen Gmbh, Hilden, Germany). Hybrid-
ization with the oligonucleotide microarray HG 
U133A (Affymetrix, California, USA) was performed 
according to Affymetrix Gene Expression Analysis 
Technical Manual (Affymetrix, California, USA). Flu-
orescence intensity was measured with the use of 
Agilent GeneArray Scanner G2500A (Agilent Tech-
nologies, California, USA).
Statistical analysis
For finding significant genes between KA, SCC, 
BCC and control samples comparative analysis 
was performed with the use of GeneSpring 12.6.1 
platform (Agilent Technologies, Inc., Santa Clara, 
CA, USA) and PL-Grid Infrastructure. The differ-
ences were analysed using the Oneway ANOVA 
test with Benjamini-Hochberg Multiple Testing 
Correction and TukeyHSD Post Hoc test. Genes 
were considered as potentially differentiating when 
FC ≥ 1.1 (fold change) and the significance level 
was set at p < 0.05.
RESULTS
mRNA concentration profiles of genes involved in 
TGFβ signalling pathways in KA, SCC, BCC and healthy 
skin margins were appointed with the use of oligonucle-
otide microarrays HG-U133A (Affymetrix). Comparative 
analysis of 10 ID mRNA for TGFβ and its receptors with 
the use of Oneway ANOVA test with Benjamini-Hoch-
berg Multiple Testing Correction showed statistically 
significant differences of TGFB1 (TGFβ1) and TGFBR3 
mRNA level (p < 0.05). TGFB1 was upregulated in 
SCC, comparing to controls.  TGFBR3 mRNA level was 
down-regulated both in SCC and KA in comparison to 
healthy skin margins.
In the next step changes in transcriptome of 
1050 mRNA of genes coding proteins involved in 
TGFβ biological activity were evaluated. The set of 
genes was created based on Affymetrix database 
searching results and literature data. Oneway ANOVA 
test showed 120 ID mRNA statistically significantly 
different in analysed groups (significance level set at 
p < 0.05) (tab. 1A). In SCC 47 ID mRNA were dif-
ferentiating comparing to controls (TukeyHSD Post 
Hoc test) (tab. 1B), among them 29 ID mRNA were 
characteristic only for SCC, 17 were common for SCC 
and KA and only one ID mRNA was common for SCC 
and BCC (tab. 2; fig. 1). KA transcriptomes showed 
40 differentially expressed ID mRNA comparing to 
controls, where 23 mRNA were characteristic only for 
KA and 4 were characteristic for BCC. Nonparamet-
ric T test with Benjamini-Hochberg Multiple Testing 
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 Correction showed 13 ID mRNA in KA and 1 ID mRNA 
in SCC, comparing to controls (p < 0.05) (tab. 3). No 
differences were found for BCC in comparison to con-
trol samples.
In the last stage of comparative analysis strength 
of mRNA in differentiation of SCC, KA and BCC from 
controls was estimated based on overrepresentation 
test results (19). Analysis revealed that among 120 ID 
mRNA indicated by Oneway ANOVA test 14 genes are 
significant for TGFβ signaling pathway and 7 genes 
are substantial for gonadotropin releasing hormone 
receptor pathway. Among 13 ID mRNA designated 
by nonparametric T test only 4 genes are significant 
for TGFβ signaling pathway (tab. 4). Diversity of fluo-
rescence signals reflecting transcriptional activity of 
genes differentiating non-melanoma skin pathologies 
from controls is shown in the figure 2.
DISCUSSION
Malignant transformation is usually not a conse-
quence of a single gene dysfunction but whole groups 
of genes involved in controlling of numerous meta-
bolic and regulatory pathways in the cell. Analysis of 
expression of individual genes involved in these path-
ways is not sufficient to assess the physiological state 
of the cells. Expression microarray technology allows 
not only for analysis of transcriptional activity of over 
20 thousand of genes in a single experiment, but also 
analysis of post-transcriptional modifications of mRNA. 
Because molecular changes precede phenotype fea-
tures this technology can improve detection of lesions 
in the initial stage of their formation. It can also pro-
vide the basis for diagnostic strategy to facilitate the 
classification of histologically indistinguishable pathol-
ogies. In some cases the classical diagnostic methods 
are insufficient for the proper distinction of keratoac-
anthoma (KA) from well-differentiated squamous cell 
carcinoma (SCC) (20, 21). Moreover, clinical forms of 
Fig. 1. Venn diagram showing number of differentiating transcripts 
in comparison to controls in groups of transcriptomes: KA – kerato-
acanthoma (Entity List 3), SCC – squamous cell carcinoma (Entity 
List 2), BCC – basal cell carcinoma (Entity List 1).
Table 1. The results of statistical analysis of 1050 IDmRNA of TGFβ responsive genes between the transcriptomes of KA – kerato-
acanthoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma, C – controls (healthy skin margins). 
A – The results of Oneway ANOVA test with Benjamini-Hochberg Multiple Testing Correction showing 120 differentiating entities 
at p < 0.05.
B – TukeyHSD Post Hoc test results. Entities found to be differentially expressed between particular groups of samples are repre-
sented by grey colour. 
A
All ID mRNA p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001
1050 120 42 27 19 4
B
Group of transcriptomes KA SCC BCC C
KA 120 17 44 40
SCC 103 120 55 47
BCC 76 65 120 5
C 80 73 115 120
Table 2. Differentiating transcripts illustrated on Venn diagram (fig. 1) characteristic for particular groups of transcriptomes of KA 
– keratoacanthoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma comparing to C – controls (healthy skin mar-





KA vs C – 40 ID mRNA
KAvsC 23
SHC1; SH3BP5; NIT1; ITGB4; ITGB4; FOXD1; DPT; UBE2I; QRICH1; MFSD10; CITED2; PGF; 
PML; ITGB4; WIPF2; DPT; DPT; SHC1; ITGA6; ZFP106; RNF141; VGLL3; NCLN 




PRDM4; ITGA6; TGFBR3; ACVR2A; PTHLH; SMAD1; PTHLH; NKX2-1; SMAD1; PTHLH; ACVR1B; 
WDR61; ARHGEF10; SMURF1; ZBTB3; C19orf54; AMIGO2
SCC vs C 29
TGFB1; PSG3; EML3; ARL4D; ICK; KRT15; INHBA; CDKN2B; IFNA14; CDKN1B; PSG9; KBP1A; 
NKX2-1; ESR2; GFR2; MGRN1; DHX30; ZC3H4; SMAD6; ROD1; PCDH1; RBM8A;NLK; RAB22A; 




BCC vs C – 4 ID mRNA
BCC vs C 4 DYRK2; ACOX3; SMAD7; DUSP22
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SCC (sore and papular) morphologically resemble not 
only KA, but also basal cell carcinoma (BCC) (20, 22). 
Therefore finding additional markers is necessary 
for improvement of diagnosis of non-melanoma skin 
pathologies. Another interesting feature of keratoac-
anthoma is its tendency to self-regression with scar-
ring (23). Molecular mechanism of this phenomenon 
is still unclear. Great expectations are associated with 
research aimed at understanding the complex function 
of TGFβ, both in tumour suppression and promotion. 
It is suggested that this cytokine may constitute one 
of the main factors responsible for modulation of can-
cer stem cells. TGFβ1 pathway is involved in transfor-
mation of human mesenchymal stem cells (MSCs) to 
cancer-associated fibroblasts (CAF), promoting tumor 
growth and metastasis (24).
In the present study transcriptomes of genes as-
sociated with the TGFβ activity in BCC, SCC, KA and 
Table 3. Nonparametric T test with Benjamini-Hochberg Multiple Testing Correction results showing mRNA differentiating ana-
lysed trascriptomes of KA – keratoacanthoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma, comparing to 
C – controls (healthy skin margins).
FC all
AK vs C SCC vs C BCC vs C
P all P < 0.05 P < 0.01 P < 0.005 P all P < 0.05 P all P < 0.05
1050 13 2 0 1050 1 1050 0
FC > 1.1 614 13 2 0 677 1 510 0
FC > 1.5 121 7 2 0 130 1 67 0
FC > 2.0 36 6 2 0 35 0 21 0
FC > 3.0 10 1 1 0 8 0 1 0
Differentiating mRNA
ITGA6; NIT1; ACVR2A; ZNF135; PTHLH; 
CITED2; PGF; PTHLH; PTHLH; WIPF2; 
ACVR1B; ZBTB3; SMURF1
ZC3H4 –
Table 4. Overrepresentation test results showing strength of differentiating mRNA of TGFβ responsive genes (displaying only 
results with p < 0.05; p-value calculated by the Binomial statistic).
All 120 mRNA (Oneway ANOVA*) 13 mRNA (T Test unpaired**) 
PANTHER Pathways Number p-value Gene symbol Number p-value Gene symbol
Unclassified 19446 73 0.00E00 6 0.00E00
TGF-beta signaling pathway 95 14 3.68E-15
SMAD7; SMAD6; SMAD3; 
SMAD1; TGFB1; GDF15; 
BMP6; INHBA; FKBP1A; 










TGFBR3; TGFB1; ACVR2A; 
ACVR1B; SMAD3; SMAD1
– – –
*Multiple Testing Correction Benjamini-Hohberg
**Bonferoni correction
Fig. 2. Normalised intensity values of fluorescence signals (mean ± standard deviation) of differentiating mRNA in KA – keratoacanthoma, 
SCC – squamous cell carcinoma, BCC – basal cell carcinoma and C – controls (healthy skin margins).
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healthy skin margins (controls) were analyzed using 
oligonucleotide microarray (Affymetrix). In the first 
stage of comparative analysis 10 ID mRNA for TGFβ 
and its receptors were evaluated. Comparing to 
healthy skin margins TGFB1 (TGFβ1) was upregulat-
ed in SCC, while TGFBR3 (TβRIII) was down-regulat-
ed both in SCC and KA. Soluble form of TβRIII binds 
to TGFβ neutralizing its tumor promoting activity in 
late stage of tumors (25). The down-regulation or the 
loss of TβRIII expression was reported in many types 
of cancer at stage of tumour progression and metas-
tasis. The loss of TβRIII expression was reported in 
breast cancer, ovarian cancer, renal cell carcinoma, 
and prostate cancer (25). The down-regulation at the 
mRNA and protein level was observed in non-small 
cell lung cancer, pancreatic adenocarcinomas, and 
well-differentiated endometrial carcinoma, as well 
as total inhibition of TβRIII expression in poorly dif-
ferentiated endometrial carcinoma (25). In our study 
down-regulation of TβRIII expression, both in SCC 
and KA, supports previous observations that KA is 
a benign variant of squamous cell carcinoma (SCC) 
(26). However, the TGFB1 mRNA was increased only 
in SCC, what suggests that intracellular signalization 
induced by TGFβ1 could not be identical in these 
two skin lesions. Consequently, comparative analysis 
of mRNA profile of genes coding proteins involved 
in TGFβ-induced signalization was performed. This 
profile was strongly changed in SCC, where 47 ID 
mRNA were differentiating comparing to controls. 
In keratoacanthoma 40 ID mRNA were differentially 
expressed, while in BCC only 5 ID mRNA were dif-
ferentiating. Moreover, 17 mRNA were common for 
both, SCC and KA, and only one mRNA was com-
mon for SCC and BCC. KA and BCC had no mutual 
mRNA. These results show that, both in SCC and 
KA, TGFβ1-induced signalization could play a crucial 
role, and reveal molecular similarity of these skin le-
sions.
To assess the strength of mRNA in differentiation of 
SCC, KA and BCC from controls overrepresentation 
test was carried out. The binomial statistics tool of the 
PANTHER (Protein ANalysis THrough Evolutionary Re-
lationships) Classification System revealed that in the 
group of 13 differentiating mRNA (nonparametric T test), 
4 mRNA are significant in TGF-beta signaling pathway: 
CITED2 (Cbp/p300-interacting transactivator, with Glu/
Asp-rich carboxy-terminal domain, 2), SMURF1 (SMAD 
specific E3 ubiquitin protein ligase 1), ACVR1B (ac-
tivin a receptor, type IB; ALK4), and ACVR2A (activin 
A receptor, type IIA; ActRIIA). CITED2 is transcriptional 
modulator inhibited by TGFβ at the posttranscriptional 
level (27). Mice lacking CITED2 expression show ab-
normal fetal lung development with aberrant differen-
tiation of alveolar epithelial cells (27). In our research 
CITED2 was significantly down-regulated in KA, with 
the highest expression in controls. SMURF1 was over-
expressed, both in KA and SCC. High expression of 
SMURF1 has been shown in human colorectal cancer, 
pancreatic cancer, and in drug resistant HNSCC (head 
and neck squamous cell carcinoma) (28). It promotes 
tumor invasiveness and correlate with cancer progres-
sion and prognosis. Both activin receptors – ACVR1B 
and ACVR2A were down-regulated in SCC and KA. 
A homozygous deletion of the activin A receptor, type IB 
was reported in pancreatic cancer, resulting in an ag-
gressive cancer phenotype (29). ActRIIA, together with 
BMPRII (Bone Morphogenetic Protein Type II Recep-
tor), is necessary for endoglin-mediated suppression 
of prostate cancer invasion (30).
CONCLUSIONS
In conclusion, mRNA profile of genes coding 
proteins involved in TGFβ-induced signalization re-
veals strong molecular similarity of SCC and KA. 
This result indicate that TGFβ biological activity 
could play a crucial role in the molecular mecha-
nism of these skin lesions development.
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